Company Name: QuantHealth
Location: Tel Aviv, Israel
Nature of Business: AI-powered clinical trial design platform
Funding Raised: $15M in Series A, culminating to a total funding of $20M
- Bertelsmann Investments
- Pitango HealthTech
- Shoni Top Ventures
- Nina Capital
- Boston Millennia Partners (Previous)
- Atooro Fund (Previous)
- Renegade Ventures (Previous)
Purpose for Funds: To drive commercial expansion, amplify product development, and expand the platform's capabilities beyond clinical trials to include regulatory support and early R&D.
Nature of Product/Service: QuantHealth's platform offers a simulator capable of predicting patient responses in clinical trials. This enables trial design teams to evaluate thousands of protocol variations and fine-tune the trial design for optimal outcomes. The AI engine, which is grounded on a colossal dataset of 350 million patients and a comprehensive biomedical knowledge-graph, boasts an impressive 86% accuracy rate in predicting clinical trial outcomes. The platform aids in addressing pivotal questions concerning trial design, indication selection, asset evaluation, and more.
- Orr Inbar, CEO
- David Dornstreich, Chief Commercial Officer
- Arnon Horev, Chief Strategy and Operations Officer
Overview: Since its inception, QuantHealth has been on the cutting edge of clinical trial design, leveraging its proprietary AI capabilities. Their solutions are trusted by prominent pharmaceutical corporations, a host of biotech companies, CROs, and other key industry stakeholders.